Osipenko, Leeza

Number of items: 15.
None
  • Osipenko, Leeza (2024). Does industry really develop less medicine with clinical benefit?—Reply. JAMA Internal Medicine, 184(5), p. 587. https://doi.org/10.1001/jamainternmed.2024.0180
  • Osipenko, Leeza (2023). Provenance, Added Clinical Benefit and Therapeutic Area of 632 medicines that entered the French market between 2008 and 2018. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.7825910
  • Osipenko, Leeza (2023). The Origin and Clinical Benefit of First-in-Class Drugs that entered the French market between 2008 and 2018. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.7823469
  • Osipenko, Leeza (2021). Ledger of data redactions in NICE Technology Appraisals. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.4618013
  • Osipenko, Leeza (2021). Quality of Evidence submitted to NICE Technology Appraisals (2000-2020). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5236357
    • Public
  • Osipenko, Leeza, Ul-Hasan, Saba Ajwat, Winberg, Debra, Prudyus, Kseniia, Kousta, Marina, Rizoglou, Artemis, Rustignoli, Isabella, Van Der Maas, Laurens (2024). Assessment of quality of data submitted for NICE technology appraisals over two decades. BMJ Open, 14(2). https://doi.org/10.1136/bmjopen-2023-074341 picture_as_pdf
  • Osipenko, Leeza, Potey, Philippe, Perez, Bernardo, Angelov, Filip, Parvanova, Iva, Ul‐hasan, Saba, Mossialos, Elias (2023). The origin of first‐in‐class drugs: innovation versus clinical benefit. Clinical Pharmacology and Therapeutics, https://doi.org/10.1002/cpt.3110 picture_as_pdf
  • Osipenko, Leeza, Potey, Philippe, Perez, Bernardo, Kupryjanczuk, Alexandra, Angelov, Filip, Schuster, Alexandra, Mossialos, Elias (2023). Provenance and clinical benefit of medicines introduced to the French market, 2008 to 2018. JAMA Internal Medicine, 184(1), 46 - 52. https://doi.org/10.1001/jamainternmed.2023.6249 picture_as_pdf
  • Jentzsch, Valerie, Osipenko, Leeza, Scannell, Jack W., Hickman, John A. (2023). Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors. JAMA network open, 6(7), E2324977. https://doi.org/10.1001/jamanetworkopen.2023.24977 picture_as_pdf
  • Nowrouzi-Kia, Behdin, Osipenko, Leeza, Eftekhar, Parvin, Othman, Nasih, Alotaibi, Sultan, Schuster, Alexandra M, Sun Suh, Hae, Duncan, Andrea (2022). The early impact of the global lockdown on post-secondary students and staff: a global, descriptive study. SAGE Open Medicine, 10, https://doi.org/10.1177/20503121221074480 picture_as_pdf
  • Osipenko, Leeza (2021). Audit of data redaction practices in NICE technology appraisals from 1999 to 2019. BMJ Open, 11(10). https://doi.org/10.1136/bmjopen-2021-051812 picture_as_pdf
  • Osipenko, Leeza (2 April 2020) The Locked-down: we need more than headline statistics to understand the impact of Covid-19. Impact of Social Sciences Blog. picture_as_pdf
  • Osipenko, Leeza (2019). Blockchain's potential to improve clinical trials-an essay by Leeza Osipenko. BMJ, 367, https://doi.org/10.1136/bmj.l5561 picture_as_pdf
  • Crispi, Francisca, Naci, Huseyin, Barkauskaite, Eva, Osipenko, Leeza, Mossialos, Elias (2018). Assessment of devices, diagnostics and digital technologies: a review of NICE medical technologies guidance. Applied Health Economics and Health Policy, https://doi.org/10.1007/s40258-018-0438-y picture_as_pdf
  • Anderson, Michael, Naci, Huseyin, Morrison, Deborah, Osipenko, Leeza, Mossialos, Elias (2018). A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, https://doi.org/10.1016/j.jclinepi.2018.09.003